DuPont de Nemours, Inc. (DD) Stock Analysis
Is DD a good investment?
DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 65.0/100 as of October 02, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet with D/E of 0.23 (74.7% below industry average of 0.91), $1.74B cash, and $1.128B annual FCF — provides strategic flexibility, recession resilience, and capacity to fund PFAS settlements trivially while sustaining buybacks that bridge the 4% revenue / 20% EPS growth gap. Main concern: Extreme valuation with no near-term catalyst for multiple compression: PEG 15.39x (47% above industry 10.44x, itself elevated), P/E 308.05x — requires full earnings normalization (net margin recovering from 0.67% toward 8-10%) over multiple years before GAAP multiples become defensible; FCF-based value ($70-85/share) implies the stock carries a 50-80% premium to intrinsic value even on generous assumptions.
Investment Summary
DuPont (DD) at $129.20 is a high-quality specialty chemicals operator trading at severely distorted GAAP multiples (P/E 308x, PEG 15.39x) due to a 0.7% net margin that masks a 14.2% operating margin — a 13.5 percentage point gap driven by non-recurring/non-cash charges below the operating line. The analytically correct valuation anchor is FCF-based: $1.128B annual free cash flow on ~500M shares implies ~$2.25 FCF/share, giving a P/FCF of ~57x at current price — still elevated, but far more defensible than the headline P/E. Analyst consensus target of $178.00 implies 37.8% upside, grounded in a secular growth thesis ('DuPont: Secular Growth And Margin Expansion Should Drive Good Upside') across healthcare, water technologies, and semiconductor end markets. The PFAS litigation overhang persists — the Connecticut firefighters' lawsuit ('3M, DuPont must face Connecticut firefighters' lawsuit') signals ongoing state-level precedent risk despite prior settlements. Balance sheet is fortress-class: D/E 0.23 vs. industry 0.91, $1.74B cash. Forward EPS growth of 9.79% next year (vs. industry average -4.03%) and 20% 5-year CAGR position DD as the sector's earnings growth leader. The stock has drifted -0.8% from $130.27 in the prior period, with no material fundamental change — anchoring to prior Buy at medium conviction.
Key Strengths
- Fortress balance sheet with D/E of 0.23 (74.7% below industry average of 0.91), $1.74B cash, and $1.128B annual FCF — provides strategic flexibility, recession resilience, and capacity to fund PFAS settlements trivially while sustaining buybacks that bridge the 4% revenue / 20% EPS growth gap
- Sector-leading forward earnings growth: forward EPS +9.79% next year vs. industry average -4.03% (343% relative outperformance) and 20.01% 5-year CAGR vs. 16.9% industry — DD is the only earnings growth story in a distressed chemicals sector, justified by secular tailwinds in Healthcare, Water Technologies (semiconductor, Asia-Pacific expansion), and industrial filtration per recent news
- Analyst consensus target $178.00 (+37.8% upside from $129.20) backed by 80/20 portfolio simplification strategy and gross margin structural advantage of 32.74% (nearly double the industry 16.78%) — confirms institutional conviction in margin normalization thesis with multiple secular catalysts including Tyvek renewable attribution launches and Water Solutions distributor expansion
Key Concerns
- Extreme valuation with no near-term catalyst for multiple compression: PEG 15.39x (47% above industry 10.44x, itself elevated), P/E 308.05x — requires full earnings normalization (net margin recovering from 0.67% toward 8-10%) over multiple years before GAAP multiples become defensible; FCF-based value ($70-85/share) implies the stock carries a 50-80% premium to intrinsic value even on generous assumptions
- Persistent dual headwinds of revenue growth lag (4.0% vs. industry 17.36%, -77% deficit — UNCHANGED for multiple periods) and PFAS litigation overhang ('3M, DuPont must face Connecticut firefighters' lawsuit' establishing state-level precedent risk for additional claims beyond the NC Fayetteville Works settlement), creating structural drag on both top-line momentum and below-the-line charges that perpetuate the operating-to-net margin gap
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability: Gross margin 32.74% (vs. industry 16.78%, +96%) confirms premium specialty positioning. Operating margin 14.24% (vs. industry 13.79%, +3.3%) shows operational efficiency. Net margin 0.67% (vs. industry -2.06%) — deeply depressed but positive in a loss-making sector. ROE 2.78% (vs. industry -2.64%) — below the 15% Buffett threshold but positive versus value-destroying peers. The operating-to-net margin gap of 13.57pp indicates massive below-the-line charges (interest, restructuring, impairments) distorting GAAP earnings. Financial Health: D/E 0.23 (74.7% below industry 0.91), cash $1.74B, FCF $1.128B — fortress balance sheet by any standard. FCF generation confirms real cash economics. Valuation: P/E 308.05x (vs. industry 35.68x, +763% premium) — distorted by depressed earnings; P/B 1.27x — alone appears reasonable; PEG 15.39x (vs. industry 10.44x, +47%) — primary metric signals extreme overvaluation even on 20% 5-year growth assumption. FCF-based intrinsic value estimate: $70-85/share at 15x FCF, implying ~50-80% premium in current stock price. Growth: Revenue growth 4.0% (vs. industry 17.36%, -77%) — significant top-line lag. Forward EPS +9.79% next year (vs. industry -4.03%) — DD growing while peers contract. 5-year EPS CAGR 20% (vs. industry 16.9%) — superior long-term earnings trajectory. Historical EPS growth 149.6% (vs. industry 200.4%) — base-effect recovery, not organic acceleration.
News Sentiment
DuPont de Nemours is navigating a complex strategic moment — transforming its sprawling industrial legacy into a focused specialty technology company while managing an ongoing legal battle over 'forever chemicals' that won't go away quietly. On the innovation front, DuPont made several moves this week that signal where the company is headed. The launch of Tyvek® with Renewable Attribution — featured in the headline 'DuPont Launches Tyvek® with Renewable Attribution for Consumer & Industrial Applications' — reflects management's push toward sustainable materials, a growing priority for corporate buyers worldwide. The company also unveiled a Sugar Separation Advisor platform ('DuPont Launches Sugar Separation Advisor to Accelerate Sugar and Sweetener Purification'), expanding its filtration and separation technology business into food processing — an area where its Water Solutions expertise translates directly. Analysts remain broadly optimistic. The neutral but constructive headline 'DuPont: Secular Growth And Margin Expansion Should Drive Good Upside' captures the institutional thesis: DD's Healthcare and Water Technologies segments are positioned in structurally growing markets — from medical devices to semiconductor-grade water treatment — that should drive earnings higher even as overall revenue grows modestly. But the legal cloud persists. Courts ruled that DuPont and 3M must face a Connecticut firefighters' lawsuit over PFAS 'forever chemicals' contamination ('3M, DuPont must face Connecticut firefighters' lawsuit over forever chemicals'), adding to the Fayetteville Works settlement and signaling that PFAS liability is a multi-year story, not a resolved chapter. For everyday investors, the message is: DuPont is a company in transition — building something better, but carrying the costs of its industrial past.
Risk Assessment
Primary risk: Valuation is the dominant concern. At P/FCF ~57x and PEG 15.39x, the stock requires flawless execution of margin normalization (net margin recovering from 0.67% to 8-10%) and sustained 20% EPS CAGR for 5 years. Any disappointment in this trajectory — particularly given only 4.0% revenue growth providing no top-line cushion — could trigger a sharp de-rating. Secondary risk: PFAS litigation is not fully resolved. The Connecticut firefighters' lawsuit ('3M, DuPont must face Connecticut firefighters' lawsuit') establishes precedent for additional state-level actions; if settlements scale materially, they will extend the below-the-line charge pressure suppressing net margins. Mitigation: Stop loss at $118.50 (-6.7% from $127.00 entry midpoint) limits downside; position size of 3.0% caps portfolio impact. The fortress balance sheet (D/E 0.23, $1.74B cash) provides time for thesis to develop, and FCF of $1.128B annually covers settlement obligations with room to spare. Macro risk: Chemicals sector cyclicality could impair even DD's premium positioning if end-market demand deteriorates across Healthcare, Water, and industrial segments simultaneously.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is DD a halal stock?
No, DuPont de Nemours, Inc. (DD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for DD?
DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 65.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is DD a good investment?
According to Plutrex AI, DD has a Buy rating (65.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in DD?
US stocks like DD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in DD?
Plutrex AI identifies the main risks for DD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.